spacer
home > ebr > spring 2018 > redefining proteomics
PUBLICATIONS
European Biopharmaceutical Review

Redefining Proteomics

Tumour suppressor p53 (TP53) is a gene, not a protein. It is rhetorically convenient but scientifically inaccurate to suggest these are morphological variants of the same thing. Human cells splice and assemble in at least nine different ways the exons present in the TP53 gene. Therefore, TP53 isoform 7 is the appropriate name for an mRNA intermediary between gene and protein. Likewise, protein does not simply swap ribonucleotides for amino acids at a 3:1 ratio.

Many residues will be variously and reversibly modified with chemical, carbohydrate, lipidatious, and/or proteinacious adducts that will impart different structures and biochemical properties; direct the protein to different locations; alter activities, functions, and interactions; and control destruction of the molecule itself – all as the larger cell sees fit. These co- and post-translational modifications (PTM) are essential to everything about proteins that makes them so. Methylated, phospho-TP53 isoform 7 is thus a protein. If a proteomic screen is not providing this level of information, is it technically even proteomic?

Mass Spectrometry: Necessary but Insufficient

Stable proteins may have no concurrently existing, corresponding mRNA. Post-transcriptional regulation means not all mRNA present within cells has such corresponding protein. To identify the protein components of a complex sample, no substitute for mass spectrometry (MS) exists, particularly in targeted approaches where one seeks to identify the presence of a particular component within complex mixtures

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Christian Loch is Chief Executive and Science Officer at AVMBioMed. He is also adjunct faculty in the Department of Chemistry at Villanova University, US, where he teaches proteomics in the graduate school. Christian has 10 years of industry experience and holds an MPH in epidemiology from the University of Washington, US, and a PhD in biochemistry from the University of Virginia, US.
spacer
Dr Christian Loch
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for twelve countries in Asia Pacific

Novo Nordisk Pharmatech A/S and DKSH, have partnered to provide high-quality cGMP quaternary ammonium compounds in twelve countries across Asia Pacific
More info >>

White Papers

e-tools enhance clinical trial performance

e-novex

In today’s ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
More info >>

 
Industry Events

ASGCT 22nd Annual Meeting

29 April - 2 May 2019, Washington Hilton, Washington, D.C

The 2019 ASGCT Annual Meeting is expected to be the largest in Society history, eclipsing the mark set by the 2018 meeting just last year. Join more than 3,500 researchers, clinicians, advocates, and industry leaders in discovering the latest science and technology surrounding gene and cell therapy.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement